Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012

In an ad hoc analysis of PRIMA, 93.2% (177/190) of niraparib-treated patients developed 1-3 lesions at first progression.• The most common sites of progression were the peritoneum (30.0%), lymph nodes (26.3%), and liver (20.5%).• Similar results were seen when patients were stratified by biomarker status, disease stage, and type of debulking surgery.• Thorough evaluation can help identify niraparib-treated patients with advanced ovarian cancer who develop oligometastases.• These patients may benefit from integration of local therapy into an ongoing, systemic, targeted maintenance regimen.